Gottlieb Points To CAR-T, Gene Therapies As Sources Of Market Competition

May 14, 2018
FDA soon will announce a set of reforms intended to make the new drug approval process more efficient and spur innovation, FDA Commissioner Scott Gottlieb told reporters during a Monday (May 14) media briefing. The agency chief pointed to gene therapies that are therapeutically equivalent to each other as having the potential to increase competition and negotiating power when it comes to prices. Gottlieb's announcement comes on the heels of President Donald Trump's newly released blueprint to lower drug prices...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.